Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

Journal of the National Cancer Institute

Volumn 89, Issue 23, 1997, Pages 1803-1809

  Miyazaki, Masahiro ^a   Nagy, Attila ^a   Schally, Andrew V ^a,b   Lamharzi, Najib ^a   Halmos, Gabor ^a   Szepeshazi, Karoly ^a   Groot, Kate ^a   Armatis, Patricia ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE]; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; LUTEINIZING HORMONE; MESSENGER RNA; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; MOUSE; NONHUMAN; OVARY CANCER;

EID: 0030656285     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.23.1803     Document Type: Article

References (33)

1. Chemotherapy of gynecologic cancers. Stephen C. Rubin, editor. Philadelphia: Lippincott-Raven, 1996:91.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46: 5-27.
3. Emons G, Schally AV. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancer. Hum Reprod 1994;9:1364-79.
4. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989;25:215-21.
5. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1984;11:251-63.
6. Chiara S, Lionetto R, Campora E, Oliva C, Merlini L, Bruzzi P, et al. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest. Eur J Cancer 1995;31A:296-301.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
8. Janaky T, Juhasz A, Bajusz S, Csernus V, Srkalovic G, Bokser L, et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci U S A 1992;89:972-6.
9. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anticancer Drugs 1992;3:109-16.
10. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, et al. LH-RH analogs with cytotoxic radicals. In: Filicori M, Flamigni C, editors. Treatment with Gn-RH analogs: controversies and perspectives. Carnforth, U.K.: Parthenon, 1996:33-44.
11. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci U S A 1996;93:7269-73.
12. Horowitz AT, Treves AJ, Voss R, Okon E, Fuks Z, Davidson L, et al. A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. Oncology 1985;42:332-7.
13. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A 1994;91: 7090-4.
14. Manetta A, Gamboa-Vujicic G, Paredes P, Emma D, Liao S, Leong L, et al. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 1995; 63:282-7.
15. Gamboa-Vujicic G, Carpenter PM, Podnos YD, Dorion G, Iravani L, Bolton D, et al. Characterization and development of UCI 107: a primary human ovarian carcinoma cell line. Gynecol Oncol 1995;58:336-43.
16. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24: 148-54.
17. Chiu KY, Loke SL, Wong KK. Improved silver technique for showing nucleolar organiser regions in paraffin wax sections. J Clin Pathol 1989;42:992-4.
18. Szepeshazi K, Korkut E, Schally AV. Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone. Am J Pathol 1991;138: 1273-7.
19. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil MV, Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci U S A 1996;93:2398-402.
20. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonists RC-3095. Proc Natl Acad Sci U S A 1997;94: 956-60.
21. Munson PJ, Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107:220-39.
22. Bernhardt G, Reile H, Birnbock H, Spruss T, Schonenberger H. Standardized kinetic micro-assay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 1992;118:35-43.
23. Varga JM, Asato N, Lande S, Lerner AB. Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells. Nature 1977;267:56-8.
24. Tritton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982;217:248-50.
25. Tritton TR. Cell surface action of adriamycin. Pharmacol Ther 1991;49:293-309.
26. Emons G, Ortmann O, Teichert HM, Fassl HG, Lohrs U, Kullander S, et al. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian cancer. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996;78:1452-60.
27. Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, et al. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a specific emphasis on treatment dose. Cancer 1989;64:1577-82.
28. Arteaga CL, Hanauske AR, Clark GM, Osborne CK, Hazarika P, Pardue RL, et al. Immunoreactive α transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res 1988;48:5023-8.
29. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognosis factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164:669-74.
30. Morishige K, Kurachi H, Amemiya K, Fujita Y, Yamamoto T, Miyake A, et al. Evidence for the involvement of transforming growth factor a and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 1991;51: 5322-8.
31. Bauknecht T, Angel P, Kohler M, Kommoss F, Birmelin G, Pfleiderer A, et al. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Classification of malignant phenotypes. Cancer 1993;71: 419-29.
32. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, et al. The prognosis value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-6.
33. Shirahige Y, Cook CB, Pinski J, Halmos G, Nair R, Schally AV. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 1994;5:1031-5.